- Home
- OZ vs SLRN Comparison
OZ vs SLRN Comparison
Compare OZ & SLRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OZ
- SLRN
- Stock Information
- Founded
- OZ 2020
- SLRN 2020
- Country
- OZ United States
- SLRN United States
- Employees
- OZ N/A
- SLRN N/A
- Industry
- OZ
- SLRN Biotechnology: Pharmaceutical Preparations
- Sector
- OZ
- SLRN Health Care
- Exchange
- OZ Nasdaq
- SLRN Nasdaq
- Market Cap
- OZ 240.7M
- SLRN 197.6M
- IPO Year
- OZ N/A
- SLRN 2023
- Fundamental
- Price
- OZ $62.01
- SLRN $2.69
- Analyst Decision
- OZ
- SLRN Hold
- Analyst Count
- OZ 0
- SLRN 5
- Target Price
- OZ N/A
- SLRN $9.60
- AVG Volume (30 Days)
- OZ 15.6K
- SLRN 2.9M
- Earning Date
- OZ 01-01-0001
- SLRN 03-27-2025
- Dividend Yield
- OZ N/A
- SLRN N/A
- EPS Growth
- OZ N/A
- SLRN N/A
- EPS
- OZ N/A
- SLRN N/A
- Revenue
- OZ $2,092,000.00
- SLRN N/A
- Revenue This Year
- OZ N/A
- SLRN N/A
- Revenue Next Year
- OZ N/A
- SLRN N/A
- P/E Ratio
- OZ N/A
- SLRN N/A
- Revenue Growth
- OZ N/A
- SLRN N/A
- 52 Week Low
- OZ $55.00
- SLRN $1.85
- 52 Week High
- OZ $82.89
- SLRN $8.59
- Technical
- Relative Strength Index (RSI)
- OZ 44.28
- SLRN 59.69
- Support Level
- OZ $60.06
- SLRN $2.54
- Resistance Level
- OZ $82.89
- SLRN $2.80
- Average True Range (ATR)
- OZ 4.61
- SLRN 0.13
- MACD
- OZ 0.23
- SLRN 0.03
- Stochastic Oscillator
- OZ 8.74
- SLRN 78.00
About OZ Belpointe PREP LLC Units
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories.
About SLRN ACELYRIN INC.
Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of of transformative medicines.